American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3408-3419

  Benson III, Al B ^a   Schrag, Deborah ^a   Somerfield, Mark R ^a   Cohen, Alfred M ^a   Figueredo, Alvaro T ^a   Flynn, Patrick J ^a   Krzyzanowska, Monika K ^a   Maroun, Jean ^a   McAllister, Pamela ^a   Van Cutsem, Eric ^a   Brouwers, Melissa ^a   Charette, Manya ^a   Haller, Daniel G ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; COLON CANCER; HIGH RISK PATIENT; HISTOLOGY; HUMAN; LYMPH NODE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL SOCIETY; MORBIDITY; ONCOLOGY; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SAMPLE; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; META ANALYSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 4344587783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.063     Document Type: Review

References (45)

1. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1973-1999. Bethesda, MD, National Cancer Institute, 2002
2. American Cancer Society: Cancer Facts and Figures 2004. Atlanta, GA, American Cancer Society, 2004
3. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
4. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
5. Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999-1005, 2002
6. Canadian Medical Association: The Canadian task force on the periodic health examination. Can Med Assoc J 121:1193-1254, 1979
7. Figueredo A, Germond C, Maroun J, et al: Adjuvant therapy for stage II colon cancer after complete resection: Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1:379-392, 1997
8. Figueredo A, Charette ML, Maroun J, et al: Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol 22: 10.1200/JCO.2004.03.087
9. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer-Verlag, 2002
10. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356-1363, 1999
11. Moertel CG, Fleming TR, Macdonald JS, et al: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13:2936-2943, 1995
12. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil - The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447-1456, 1989
13. Taal BG, Van Tinteren H, Zoetmulder FA, et al: Adjuvant 5FU plus levamisole in colonic or rectal cancer: Improved survival in stage II and III. Br J Cancer 85:1437-1443, 2001
14. Panettiere FJ, Goodman PJ, Costanzi JJ, et al: Adjuvant therapy in large bowel adenocarcinoma: Long-term results of a Southwest Oncology Group Study. J Clin Oncol 6:947-954, 1988
15. Wolmark N, Fisher B, Rockette H, et al: Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 80:30-36, 1988
16. The Colorectal Cancer Chemotherapy Study Group of Japan: Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. Jpn J Clin Oncol 25:91-103, 1995
17. Taylor I, Machin D, Mullee M, et al: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 72:359-363, 1985
18. Fielding LP, Hittinger R, Grace RH, et al: Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 340:502-506, 1992
19. Wolmark N, Rockette H, Wickerham DL, et al: Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 8:1466-1475, 1990
20. Swiss Group for Clinical Cancer Res (SAKK): Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345:349-353, 1995
21. Beart RW Jr, Moertel CG, Wieand HS, et al: Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion: A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 125:897-901, 1990
22. Liver Infusion Meta-analysis Group: Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 89:497-505, 1997
23. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
24. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
25. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300, 1998
26. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
27. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
28. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
29. de Gramont A, Banzi M, Navarro M, et al: Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc Am Soc Clin Oncol 22:253, 2003 (abstr 1015)
30. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122: 321-326, 1995
31. Swanson RS, Compton CC, Stewart AK, et al: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10:65-71, 2003
32. Greene FL, Stewart AK, Norton HJ: A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg 236:416-421, 2002
33. Le Voyer TE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912-2919, 2003
34. Gill S, Loprinzi C, Sargent D, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004
35. Compton CC, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 979-994, 2000
36. Graziano F, Cascinu S, Staccioli MP, et al: Potential role and chronology of abnormal expression of the deleted in colon cancer (DCC) and the p53 proteins in the development of gastric cancer. http://www.biomedcentral.com/ content/pdf/1471-2407-1-9.pdf
37. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
38. Compton CC: Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol 16:376-388, 2003
39. Mayo Clinic: Adjuvant systemic therapy for resected colon cancer. http://www.mayoclinic. com/calcs/colon/input.cfm
40. Loprinzi CL, Thome SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19:972-979, 2001
41. Sonpavde G: Communicating the value of adjuvant chemotherapy. J Clin Oncol 21:948-949, 2003
42. Chao C, Studts JL, Abell T, et al: Adjuvant chemotherapy for breast cancer: How presentation of recurrence risk influences decision-making. J Clin Oncol 21:4299-4305, 2003
43. Wieand H: Is relative risk reduction a useful measure for patients or families who must choose a method of treatment? J Clin Oncol 21:4263-4264, 2003
44. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28:20-24, 2001
45. Ravdin PM, Siminoff IA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998